長飛光纖(601869.SH)與中國華信及上海諾基亞貝爾簽署銷售及採購框架協議
格隆匯1月23日丨長飛光纖(601869.SH)公佈,公司擬與中國華信郵電科技有限公司(以下簡稱“中國華信”)及其附屬公司簽署銷售及採購框架協議,與上海諾基亞貝爾股份有限公司(以下簡稱“上海諾基亞貝爾”)及其附屬公司簽署採購框架協議。
集團擬向中國華信及其附屬公司銷售光纖、光纜及提供項目施工服務。集團向中國華信及其附屬公司銷售商品及提供服務交易金額上限為人民幣1.00億元,向中國華信及其附屬公司採購商品交易金額上限為人民幣2.00億元。
同時,擬向中國華信及其附屬公司、上海諾基亞貝爾及其附屬公司採購通信設備產品。集團向上海諾基亞貝爾及其附屬公司採購商品交易金額上限為人民幣1.00億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.